Sage Journals: Discover world-class research

Abstract

Background:

The prostatic urethral lift (UroLift) is a minimally invasive surgical procedure for benign prostatic hyperplasia (BPH) that preserves erectile and ejaculatory function, making it attractive to younger men. However, its impact on prostate-specific antigen (PSA) levels, crucial for prostate cancer screening, is not well understood. This study aimed to evaluate PSA trends following UroLift and assess changes in international prostate symptom scores (IPSS) and the effects of discontinuing 5-alpha reductase inhibitors (5-ARIs).

Methods:

We retrospectively analysed 201 patients who underwent UroLift at a single institution between March 2017 and December 2019. Patients with preoperative and postoperative PSA measurements were included. PSA levels were assessed at various time points postoperatively, and IPSS scores were evaluated for symptomatic changes. The influence of 5-ARI discontinuation on PSA levels was also examined. Statistical analyses were conducted using Wilcoxon signed-rank and McNemar’s tests, with p < 0.05 considered significant.

Results:

A statistically significant increase in median PSA was observed at 1–3 months (2.47 ng/mL, p = 0.003), 6 months (2.40 ng/mL, p = 0.001), 1 year (2.25 ng/mL, p < 0.001), and beyond 1 year (1.85 ng/mL, p < 0.001) post-UroLift, compared to the preoperative median of 1.60 ng/mL. IPSS scores improved significantly, with a median reduction of 11 points (p < 0.001). Twenty-four percent of our cohort utilised a 5-ARI preoperatively and discontinued it postoperatively, potentially contributing to the PSA increase. No prostate cancer was detected in patients with suspicious PSA trends who underwent further evaluation.

Conclusions:

PSA levels increased slightly but significantly following UroLift, potentially influenced by 5-ARI discontinuation. Despite this rise, no cases of prostate cancer were identified. These findings underscore the need for continued PSA monitoring post-UroLift and suggest further research to clarify the clinical implications of these PSA trends.

Keywords

UroLift PSA prostate cancer screening BPH minimally invasive surgery

Get full access to this article

View all access options for this article.

References

McNicholas

TA.

Benign prostatic hyperplasia and new treatment options—A critical appraisal of the UroLift system. Med Devices (Auckl) 2016; 9: 115–123.

Roehrborn

Gange

Shore

, et al. The prostatic urethral lift for treatment of lower urinary tract symptoms associated with prostatic enlargement due to benign prostatic hyperplasia: The LIFT study. J Urol 2013; 190: 2161–2167.

Roehrborn

Rukstalis

Barkin

, et al. Three-year results of the prostatic Urethral L.I.F.T. Study. Can J Urol 2015; 22: 7772–7782.

Chin

Bolton

Jack

, et al. Prostatic urethral lift: Two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology 2012; 79: 5–11.

Eure

Gange

Walter

, et al. Real-world evidence of Prostatic Urethral Lift confirms pivotal clinical study results: 2-year outcomes of a retrospective multicenter study. J Endourol 2019; 33: 576–584.

Rukstalis

Rashid

Bogache

, et al . A 24-month durability after crossover to the Prostatic Urethral Lift from randomized, blinded sham. BJU Int 2016; 118: 14–22.

Sønksen

Barber

Speakman

, et al. Prospective, randomized multinational study of Prostatic Urethral Lift versus transurethral resection of the prostate: 12-month results from the BPH6 Study. Eur Urol 2015; 68: 643–652.

Perera

Roberts

Doi

, et al. Prostatic Urethral Lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: A systematic review and meta-analysis. Eur Urol 2015; 67: 704–713.

Feiertag

Clark

JY.

National trends in surgical management for benign prostatic hyperplasia from2013 to 2019 in the United States. Urol Pract 2024; 11(2): 303–311

10.

Fonseca

Gomes

Meireles

, et al. Prostate-specific antigen levels following transurethral resection of the prostate. Int Braz J Urol 2008; 34(1): 41–48.

11.

Lourenço

Campos

Lousã

PSA kinetics after holmium laser enucleation of the prostate (HoLEP). World J Urol 2017; 35: 647–652.

12.

Djavan

Zlotta

Kratzik

, et al. PSA kinetics in untreated, symptomatic patients with benign prostatic hyperplasia: Relation to prostate volume and age. Eur Urol 1999; 36: 305–309.

13.

Bhat

Blachman-Braun

Herrmann

TRW

, et al. Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction. World J Urol 2022; 40(4): 889–905.

14.

Guess

Heyse

Gormley

The effect of finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1992; 22: 31–37.

15.

Andriole

Guess

Epstein

, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial. Urology 1998; 52: 195–202.

16.

Helfand

Anderson

Fought

, et al. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia. Urology 2009; 74(1): 177–183.

17.

Roehrborn

Chin

Woo

The UroLift implant: Mechanism behind rapid and durable relief from prostatic obstruction. Prostate Cancer Prostatic Dis 2022; 25: 79–85.

Prostate cancer screening following UroLift

Abstract

Background:

Methods:

Results:

Conclusions:

Keywords

Get full access to this article

References